Here are the 10-K annual reports from STERIS plc (STE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow STE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STE filings page.
STERIS plc files its annual report describing a diversified infection-prevention business built around three segments: Healthcare, Applied Sterilization Technologies and Life Sciences. The company emphasizes consumables, capital equipment, contract sterilization and related services sold globally to hospitals, device makers and biopharma companies.
As of September 30, 2025, non‑affiliates held ordinary shares with an aggregate market value of $24,222.3 million, and 97,602,485 ordinary shares were outstanding as of May 27, 2026. Capital equipment backlog reached $490.7 million at March 31, 2026, reflecting higher orders in Healthcare and Life Sciences.
STERIS highlights strong quality and regulatory performance, reporting no FDA or regulatory enforcement actions and no Class I recalls in fiscal 2026, 2025 or 2024. The company also reports industry‑leading safety metrics, broad patent and trademark portfolios, and detailed environmental, social and governance initiatives, including greenhouse‑gas tracking and formal corporate responsibility governance.